DexCom, Inc. $DXCM Shares Purchased by Sendero Wealth Management LLC

Sendero Wealth Management LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 242.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 36,329 shares of the medical device company’s stock after buying an additional 25,710 shares during the period. Sendero Wealth Management LLC’s holdings in DexCom were worth $3,171,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the company. Valeo Financial Advisors LLC raised its holdings in shares of DexCom by 23.7% during the second quarter. Valeo Financial Advisors LLC now owns 10,250 shares of the medical device company’s stock valued at $895,000 after acquiring an additional 1,962 shares during the period. DAVENPORT & Co LLC lifted its holdings in shares of DexCom by 55.0% in the second quarter. DAVENPORT & Co LLC now owns 69,943 shares of the medical device company’s stock valued at $6,105,000 after purchasing an additional 24,807 shares in the last quarter. Financial Insights Inc. acquired a new stake in shares of DexCom in the second quarter worth $267,000. QRG Capital Management Inc. grew its holdings in shares of DexCom by 14.2% during the second quarter. QRG Capital Management Inc. now owns 25,978 shares of the medical device company’s stock valued at $2,268,000 after buying an additional 3,229 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC acquired a new position in DexCom during the second quarter valued at $686,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Kyle Malady sold 667 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Jon Brown sold 500 shares of the firm’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares of the company’s stock, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock valued at $564,733 in the last 90 days. Insiders own 0.32% of the company’s stock.

DexCom Stock Up 0.9%

DXCM opened at $67.05 on Monday. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The business has a 50 day moving average of $76.31 and a 200-day moving average of $77.93. The stock has a market capitalization of $26.29 billion, a price-to-earnings ratio of 46.56, a P/E/G ratio of 1.41 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm earned $0.43 EPS. DexCom’s revenue for the quarter was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

DXCM has been the subject of a number of research reports. Truist Financial initiated coverage on DexCom in a research report on Monday, June 16th. They set a “buy” rating and a $102.00 price objective for the company. Robert W. Baird decreased their price target on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a report on Friday, September 26th. Barclays boosted their price objective on shares of DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 30th. Mizuho increased their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 16th. Finally, Oppenheimer cut shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $98.32.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.